Crucial Considerations in Monitoring Process Performance and Product Quality - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Crucial Considerations in Monitoring Process Performance and Product Quality
The author outlines key considerations for carrying out a structured approach to monitoring process performance and ensuring product quality.

Pharmaceutical Technology
Volume 34, pp. S38-S42

Process monitoring systems

The author's experience has shown that there are important considerations to take into account when designing, implementing, and operating process monitoring systems. The first of these is process understanding—that is, a deep knowledge of the variables that drive the process, which enables the accurate prediction of process performance. Effective application of QbD will result in better process understanding.

It is also crucial to understand the sources and magnitudes of measurement variation, in particular the repeatability and reducibility of the measurement of the process parameters. Gage R&R studies are an effective method for measuring the repeatability and reproducibility of the measurement methods used (6). Ruggedness studies are effective for determining method robustness for measuring typical variations that occur during the routine use of the method (8).

A systematic method is necessary to keep track of special-cause variation and to determine whether a systemic problem exists. This information can then be used to improve the process.

Two problems often observed related to monitoring systems include data not being analyzed routinely, and not taking action when significant sources of variation are identified. Regular management review and accountability can address both problems.

When a systematic approach is used, including regular review and action, the result is effective process monitoring. More importantly, high-quality pharmaceuticals are provided to the patient.

Ronald D. Snee, PhD, is founder and president of Snee Associates, 10 Creek Crossing, Newark, DE 19711,


1. R.D. Snee, Pharm. Technol. 33 (10), web exclusive, (2009).

2. J.C. Berridge, Pharm. Engin. 36–39 (2009).

3. J. Oakland, Statistical Process Control (Elsevier, New York, NY 2008).

4. D.C. Montgomery, Introduction to Statistical Quality Control, 6th Edition (John Wiley and Sons, New York, NY, 2009).

5. R.D. Snee and R.W. Hoerl, Leading Six Sigma—A Step by Step Guide (FT Press, Prentice Hall, New York, NY, 2003).

6. R.D. Snee and R.W. Hoerl, Six Sigma Beyond the Factory Floor: Deployment Strategies for Financial Services, Health Care and the Rest of the Real Economy (FT Pearson, Prentice Hall, New York, NY, 2005).

7. R.D. Snee and E. C. Gardner, Quality Progress 56–59 (2008).

8 M. Schweitzer et al., Pharm. Technol. 34 (2) 52–59 (2010).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here